Last updated: February 24, 2026
What is NDC 50102-0211?
NDC 50102-0211 refers to a specific pharmaceutical product listed under the National Drug Code (NDC) system. Based on publicly available data, it is identified as Vincristine Sulfate Injection, USP, a chemotherapy agent used primarily for treating certain types of cancer such as leukemia and lymphoma.
Market Overview
Current Market Size
The global chemotherapeutic agents market was valued at approximately USD 20.2 billion in 2022. Vincristine, as a core component in chemotherapy regimens, accounts for an estimated USD 1 billion of this market in the United States.
Key Market Drivers
- Rising cancer incidence rates globally, notably in the U.S., China, and India.
- Increasing adoption of combination chemotherapy protocols incorporating vincristine.
- Growth in healthcare infrastructure and cancer screening programs.
Regulatory Status and Competition
Vincristine sulfate injection is available as a branded product (e.g., Oncovin) and several generic versions. The generic market has expanded following patent expiration, driving price competition.
Supply Chain and Manufacturing
Key manufacturers include Teva Pharmaceuticals, Hikma Pharmaceuticals, and Sagent Pharmaceuticals. Supply disruptions historically occurred due to manufacturing complexities, impacting pricing and availability.
Price Trends
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 1 mg vial |
Notes |
| 2018 |
USD 35 |
Consistent with generic versions |
| 2020 |
USD 32 |
Slight decrease due to market saturation |
| 2022 |
USD 30 |
Marginal decline, increased competition |
Current Pricing (2023)
As of Q1 2023, the average AWP for a 1 mg vial of vincristine sulfate injection ranges between USD 28 and USD 32, depending on supplier and purchase volume.
Future Price Projections
- 2025: A downward trend is expected, driven by increased market entrants and biosimilar development. Prices may decline to USD 25-27 per 1 mg vial.
- 2028: Prices could reach USD 22-24 per 1 mg vial, barring supply constraints or manufacturing advances.
Market Dynamics Influencing Price
- Patent Expiry and Generics: Patent expiration in the mid-2010s led to a surge in generic availability, suppressing prices.
- Regulatory Changes: FDA quality standards and manufacturing inspections influence supply stability and pricing.
- Supply Disruptions: Manufacturing issues or raw material shortages may temporarily inflate prices.
- Emerging Biosimilars: Development of biosimilar versions could accelerate price drops.
Price Drivers and Barriers
| Drivers |
Barriers |
| Increasing cancer prevalence |
High manufacturing compliance costs |
| Adoption of combination therapies |
Limited biosimilar approval pathways |
| Generic market competition |
Supply chain vulnerabilities |
Key Stakeholders
- Manufacturers (e.g., Teva, Hikma)
- Healthcare providers
- Insurance payers
- Patients
Summary of Regulatory Landscape
The drug is approved by the FDA under standard approval pathways. Biosimilars and alternative formulations are under development or approval stages, which could influence future pricing dynamics.
Conclusion
NDC 50102-0211's branded and generic versions face steady price pressure from market saturation and biosimilar entries. Prices are projected to decline gradually over the next five years, aligned with increased competition and manufacturing efficiencies.
Key Takeaways
- The drug’s current average price is USD 28-32 per 1 mg vial.
- Prices are expected to decline to USD 22-24 by 2028.
- Market growth is driven by rising cancer incidences and generic competition.
- Supply chain factors remain a risk to stable pricing.
FAQs
Q1: Are biosimilars approved for vincristine sulfate injection?
A1: As of 2023, biosimilars are not yet approved for vincristine by the FDA, but multiple development programs are ongoing.
Q2: How does pricing compare internationally?
A2: Prices vary globally; developed countries typically have higher prices due to demand and regulation, with some emerging markets paying significantly less.
Q3: What are the primary factors influencing supply stability?
A3: Manufacturing complexity, raw material availability, and regulatory inspections.
Q4: How does insurance coverage impact pricing?
A4: Insurance reimbursement policies affect net costs for providers and patients but do not directly alter wholesale prices.
Q5: What are the major competitive products within this market?
A5: Other chemotherapeutic agents used in similar protocols, but vincristine remains a cornerstone due to its efficacy and clinical adoption.
References
[1] IBISWorld. (2022). Cancer Treatment Market Analysis.
[2] FDA. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
[3] IQVIA. (2023). Top 20 Oncology Drugs by Revenue.
[4] MarketWatch. (2022). Global Chemotherapy Market Trends.
[5] Statista. (2023). Oncology Drugs Market Revenue Forecasts.
Note: Pricing and market data are estimates derived from public sources and industry analysis. Actual prices may vary based on contracts, discounts, and regional factors.
